ABC008

DRUG3 trials

Sponsors

Abcuro, Inc.

Conditions

Inclusion Body MyositisT-cell Large Granular Lymphocytic Leukemia

Phase 1

A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)

CompletedNCT04659031

Abcuro, Inc.Inclusion Body Myositis

Start: 2021-05-25End: 2025-01-10Updated: 2025-02-20

ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

CompletedNCT05532722

Abcuro, Inc.T-cell Large Granular Lymphocytic Leukemia

Start: 2022-09-28End: 2026-03-31Updated: 2026-05-06

Phase 2

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

CompletedNCT05721573

Abcuro, Inc.Inclusion Body Myositis

Start: 2023-02-28End: 2025-11-27Updated: 2026-01-29